Invention Grant
- Patent Title: Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
-
Application No.: US15016856Application Date: 2016-02-05
-
Publication No.: US09724330B2Publication Date: 2017-08-08
- Inventor: George W. Muller , Peter H. Schafer , Hon-Wah Man , Chuansheng Ge
- Applicant: Celgene Corporation
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: A61K31/4035
- IPC: A61K31/4035 ; C07D209/44 ; C07C317/28 ; C07D209/48 ; A61K45/06
![Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione](/abs-image/US/2017/08/08/US09724330B2/abs.jpg.150x150.jpg)
Abstract:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
Public/Granted literature
Information query
IPC分类: